Three times a charm

Momenta and CSL are betting on an Fc trimer for autoimmunity

With this month’s deal between Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) and CSL Ltd. (ASX:CSL), the partners are hoping to take IVIG therapy for autoimmune diseases to the next level by homing in on the cornerstone of how the therapy works - Fcγ receptor (FCGR) inhibition. The goal is to define the optimal number and composition of Fc domains required to recapitulate the breadth of IVIG activity, but produce greater potency.

The deal includes Momenta’s lead candidate M230,

Read the full 763 word article

User Sign In